Fulltext

Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment

Rabea S 1 , Alanazi FK 2 , Ashour AE 3 , Salem-Bekhit MM 2 , Yassin AS 4 , Moneib NA 4 Show all authors , Hashem AEM 5 , Haq N 2

Affiliations 

  • 1 College of Pharmacy, Al-Maarefa University, P.O. Box 71666, Riyadh 11597, Saudi Arabia
  • 2 Kayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
  • 3 Department of Basic Medical Sciences, Kulliyyah of Medicine, International Islamic University Malaysia, Bandar Indera Mahkota Campus, Pahang Darul Makmur, Malaysia
  • 4 Department of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11652, Egypt
  • 5 Faculty of Pharmacy, British University in Egypt (BUE), Cairo 11837, P.O. Box 43, Egypt
Saudi Pharm J, 2020 Oct;28(10):1253-1262.
PMID: 33132719 DOI: 10.1016/j.jsps.2020.08.016

Abstract

Cell- based targeted delivery is recently gain attention as a promising platform for delivery of anticancer drug in selective and efficient manner. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical application as targeted drug delivery system (TDDS). In the current work, Salmonellas' BGs was utilized for the first time as hepatocellular cancer (HCC) in-vitro targeted delivery system. Successful BGs loading and accurate analysis of doxorubicin (DOX) were necessary steps for testing the applicability of DOX loaded BGs in targeting the liver cancer cells. Loading capacity was maximized to reach 27.5 µg/mg (27.5% encapsulation efficiency), by incubation of 10 mg BGs with 1 mg DOX at pH 9 in constant temperature (25 °C) for 10 min. In-vitro release study of DOX loaded BGs showed a sustained release (182 h) obeying Higuchi sustained kinetic release model. The death rate (tested by MTT assay) of HepG2 reached to 64.5% by using of 4 μg/ml, while it was about 51% using the same concentration of the free DOX (P value 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications